How Can Erythropoeitin-Stimulating Agent Use be Reduced in Chronic Dialysis Patients?
The “Forgotten Adjunct Therapy”: The Link Between ESA Use and Control of Hyperparathyroidism in Chronic Kidney Disease
Version of Record online: 5 JUN 2013
© 2013 Wiley Periodicals, Inc.
Seminars in Dialysis
Volume 26, Issue 5, pages 537–540, September–October 2013
How to Cite
Battistella, M., Chan, C. T. (2013), How Can Erythropoeitin-Stimulating Agent Use be Reduced in Chronic Dialysis Patients?. Seminars in Dialysis, 26: 537–540. doi: 10.1111/sdi.12106
- Issue online: 16 SEP 2013
- Version of Record online: 5 JUN 2013
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.